Eprobemide

Eprobemide (CAS No.: 87940-60-1) is a synthetic small-molecule monoamine oxidase A (MAO-A) inhibitor characterized as a reversible and non-competitive modulator of enzymatic activity, primarily affecting the oxidative deamination of monoamine neurotransmitters such as serotonin. As a pharmacologically active compound historically developed for antidepressant applications, it serves as a valuable tool in neuropharmacology and psychiatric research for investigating monoaminergic signaling pathways and mood regulation mechanisms. Eprobemide has been shown to alter behavioral outcomes in preclinical models, including reducing immobility in rodent forced swim assays, supporting its functional impact on central neurotransmission. Its inhibitory activity is generally observed within low micromolar to submicromolar ranges typical for MAO-A modulators, although experimental conditions may influence potency. In research settings, eprobemide is utilized to probe MAO-A-dependent metabolic pathways, evaluate drug–target interactions, and support the development of novel therapeutics targeting affective disorders, with dosing and concentration parameters adapted to specific in vitro or in vivo experimental designs.